09:19 AM EST - NeonMind Biosciences : Announces today it has filed a new patent application with the United States Patent and Trademark Office related to a novel mechanism of weight loss targeted to specific fat subtypes. The provisional patent application includes data derived from NeonMind's recent preclinical animal study, incorporating novel findings which indicate, in addition to reiterating weight modulation effects of psilocybin seen in previous studies, that the targeted reduction of specific fat subtypes may have beneficial effects on metabolic and cardiovascular health. The filing strengthens NeonMind's growing IP portfolio and differentiates the commercial profiles of its drug candidates. NeonMind Biosciences
shares C.NEON are trading unchanged at $0.06.
